Effects of Nebivolol Versus Metoprolol Succinate on Endothelial Function (NEMENDAS)
An impairment of endothelial function plays the central role in the pathogenesis of cardiovascular diseases and their complications. Most of cardiovascular risk factors are known to impair endothelial function and the established disease further aggravates endothelial dysfunction.
The aim of the present study is to investigate the effects of nebivolol or metoprolol succinate on endothelial function and large artery stiffness.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Comparison the Effects of Nebivolol Versus Metoprolol Succinate on Endothelial Function and Large Artery Stiffness|
- Effects of nebivolol and metoprolol on endothelial function [ Time Frame: 12 months ] [ Designated as safety issue: No ]High-fidelity micromanometer (applanation tonometry) from both wrists and PWA, which is to be performed of the systolic portion (SphygmoCor Px, version 7.0) of the pulse curve.
- Change in carotid artery intima-media thickness [ Time Frame: 12 months ] [ Designated as safety issue: No ]Ultrasound scanner,with an 12 MHz transducer. Longitudinal images from 3 projections (anterolateral, lateral, and posterolateral) are measured for the common carotid artery, carotid bulb, and internal carotid artery
- Change in left ventricular mass index, systolic and diastolic function [ Time Frame: 12 months ] [ Designated as safety issue: No ]2-dimensional echocardiography using the standard apical 4-chamber view
- Arterial Compliance [ Time Frame: 12 months ] [ Designated as safety issue: No ]Peripheral blood pressure and arterial waveform to be measured in the dominant arm by a Cardiovascular Profiling Instrument
|Study Start Date:||March 2006|
|Study Completion Date:||December 2009|
|Primary Completion Date:||December 2008 (Final data collection date for primary outcome measure)|
Active Comparator: metoprolol, tablets
metoprolol succinate 50-100 mg orally daily for one year
Drug: metoprolol succinate
once daily 50 or 100 mg for one year
Other Name: Corvitol
nebivolol 5 mg capsule once daily for one year
once daily 5 mg capsule for one year
Other Name: Nebilet
The aim of this study was to compare the effects between the vasodilating β-blocker nebivolol and the cardioselective β-blocker metoprolol succinate on aortic blood pressure and left ventricular wall thickness. We conducted a randomized, double-blind study in 80 hypertensive patients. Patients received either nebivolol 5 mg or metoprolol succinate 50-100 mg daily for one year. Their heart rate, central and brachial blood pressure, mean arterial pressure, augmentation index, carotid-femoral pulse wave velocity and left ventricular wall thickness were measured at baseline and at the end of the study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01248338
|Cardiology Clinic of Tartu University Clinics|
|Tartu, Estonia, 51014|
|Principal Investigator:||Jaan Eha, Professor||Cardiology Clinic of Tartu University Clinics|